Volume 18, Number 11—November 2012
Research
Community Outbreak of Adenovirus, Taiwan, 2011
Table 1
Characteristic | All | Severe infection, n = 31 | Nonsevere infection, n = 171 | p value |
---|---|---|---|---|
Median age, mo (range) | 40 (1–189) | 36 (1–185) | 41 (2–189) | 0.287 |
Male sex | 115 (57) | 21 (68) | 94 (55) | 0.186 |
Contact history | 119 (59) | 15 (48) | 104 (61) | 0.196 |
Median hospitalization, d (range) | 5 (1–126) | 18 (4–126) | 5 (1–44) | <0.001 |
Death rate | 7 (4) | 7 (23) | 0 (0) | <0.001 |
Any underlying disease | 76 (38) | 24 (77) | 52 (30) | <0.001 |
Prematurity |
36 (18) | 8 (26) | 28 (16) | 0.207 |
Cardiopulmonary† |
31 (15) | 12 (39) | 19 (11) | <0.001 |
Neurologic‡ |
25 (12) | 19 (61) | 6 (4) | <0.001 |
Hematologic§ |
2 (1) | 1 (3) | 1 (0.6) | 0.284 |
Metabolic¶ |
7 (4) | 4 (13) | 3 (2) | 0.012 |
Immunodeficiency# |
1 (0.5) | 1 (3) | 0 (0) | 0.153 |
*Values are no. (%) patients except as indicated. Severe infection indicates patients who were admitted to the intensive care unit.
†Congenital heart diseases (12), asthma (11), chronic lung disease (4), tracheobronchial stenosis (2), and laryngo-tracheo-bronchomalacia (2).
‡Cerebral palsy, epilepsy, and psychomotor retardation.
§Acute myeloid leukemia and Burkitt’s leukemia.
¶Pompe disease, metachromatic leukodystrophy, glycogen storage disease, isovaleric acidemia, short-chain acyl-coA dehydrogenase deficiency, renal tubular acidosis, and mitochondrial disease.
#Hypogammaglobulinemia.
1These authors contributed equally to this article.
Page created: October 16, 2012
Page updated: October 16, 2012
Page reviewed: October 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.